We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Aureus Pharma Joins MDL® Isentris® Alliance

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Aureus Pharma Joins MDL® Isentris® Alliance"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Elsevier MDL has announced that Aureus Pharma has joined the MDL® Isentris® Alliance as a preferred partner.

In addition, Aureus plans to deliver its high-quality content in MDL® Direct format. This will accelerate drug discovery workflows for MDL Isentris customers by enabling them to access Aureus content via the MDL® Isentris® informatics system.

Chemistry and biology content from Aureus includes detailed experimental activity data mined from the literature related to important drug classes (including GPCRs, ion channels and kinases) as well as other drug safety topics (ADME/drug-drug interactions and the hERG channel).

The partnership agreement permits Aureus Pharma to augment its own commercial knowledge databases with the industry-leading chemical representation and reaction searching performance of the MDL® Direct data cartridge.

The MDL Direct chemistry search engine accelerates R&D workflows by combining full reaction transformation searching, unsurpassed chemistry sophistication and proven performance on databases with over five million reactions and at least 20 million structures.

"Using the capabilities of MDL Isentris to integrate Aureus Pharma's comprehensive chemistry and biology content management system with other proprietary and commercial information will accelerate knowledgedriven discovery," said Jason Theodosiou, CEO of Aureus Pharma.

“We are especially pleased by the opportunity to enhance the usability and performance of our knowledge databases with MDL Direct cartridge technology,” Theodosiou added.

“Aureus Pharma joins a growing community of informatics companies that is working with Elsevier MDL to offer scientists comprehensive content solutions through the integrating Isentris system,” commented Lars Barfod, President and CEO of Elsevier MDL.

“Making Aureus’s extensive chemical and biological data available via Isentris reinforces our promise to the market that Isentris offers researchers critical multidisciplinary content across the discovery spectrum.”